Patients & CaregiversHealthcare ProfessionalsWorldwide
HomeAbout MerckProductsNewsroomInvestor RelationsCareersResearchLicensingThe Merck Manuals
THE MERCK MANUAL MEDICAL LIBRARY: The Merck Manual of Diagnosis and Therapy
Tips for better results
ABCDEFGHI
JKLMNOPQR
STUVWXYZ

Section

Subject

Topics

Hospital-Acquired Pneumonia

Update Me

Hospital-acquired pneumonia develops at least 48 h after hospitalization. The most common pathogens are gram-negative bacilli and Staphylococcus aureus; drug-resistant organisms are an important concern. Symptoms and signs are the same as those for community-acquired pneumonia, but in ventilated patients, pneumonia may also manifest as worsening oxygenation and increased tracheal secretions. Diagnosis is suspected on the basis of clinical presentation and chest x-ray and is confirmed by blood culture or bronchoscopic sampling of the lower respiratory tract. Treatment is with antibiotics. Overall prognosis is poor, due in part to comorbidities.

Hospital-acquired pneumonia includes ventilator-associated pneumonia, postoperative pneumonia, and pneumonia that develops in unventilated but otherwise moderately or critically ill hospitalized inpatients.

Etiology

The most common cause is microaspiration of bacteria that colonize the oropharynx and upper airways in seriously ill patients.

Risk factors: Endotracheal intubation with mechanical ventilation poses the greatest overall risk; ventilator-associated pneumonia constitutes > 85% of all cases, with pneumonia occurring in 17 to 23% of ventilated patients. Endotracheal intubation breaches airway defenses, impairs cough and mucociliary clearance, and facilitates microaspiration of bacteria-laden secretions that pool above the inflated endotracheal tube cuff. In addition, bacteria form a biofilm on and within the endotracheal tube that protects them from antibiotics and host defenses.

In nonintubated patients, risk factors include previous antibiotic treatment, high gastric pH (from stress ulcer prophylaxis therapy), and coexisting cardiac, pulmonary, hepatic, and renal insufficiency. Major risk factors for postoperative pneumonia are age > 70, abdominal or thoracic surgery, and dependent functional status.

Pathogens: Pathogens and antibiotic resistance patterns vary significantly among institutions and can vary within institutions over short periods (eg, month to month). In general, the most important pathogen is Pseudomonas aeruginosa, which is especially common in pneumonias acquired in intensive care settings and in patients with cystic fibrosis, neutropenia, advanced AIDS, and bronchiectasis. Other important pathogens include enteric gram-negative bacteria (Enterobacter sp, Klebsiella pneumoniae , Escherichia coli , Serratia marcescens , Proteus sp, Acinetobacter sp) and both methicillin-sensitive and methicillin-resistant Staphylococcus aureus.

S. aureus , pneumococcus, and Haemophilus influenzae are most commonly implicated when pneumonia develops within 4 to 7 days of hospitalization, whereas enteric gram-negative organisms become more common with increasing duration of intubation.

Prior antibiotic treatment greatly increases the likelihood of polymicrobial infection; resistant organisms, particularly methicillin-resistant S. aureus; and Pseudomonas infection. Infection with a resistant organism markedly worsens mortality and morbidity.

High-dose corticosteroids increase the risk of Legionella and Pseudomonas infections.

Symptoms, Signs, and Diagnosis: Symptoms and signs in nonintubated patients are generally the same as those for community-acquired pneumonia (see Pneumonia: Symptoms and Signs). Pneumonia in critically ill, mechanically ventilated patients more typically causes fever and increased respiratory and/or heart rate or changes in respiratory parameters, such as an increase in purulent secretions or worsening hypoxemia. Noninfectious causes of pulmonary deterioration, such as acute respiratory distress syndrome (ARDS), pneumothorax, and pulmonary edema, must be excluded.

Diagnosis is imperfect. In practice, hospital-acquired pneumonia is often suspected on the basis of the appearance of a new infiltrate on a chest x-ray that is taken for evaluation of new symptoms or signs or of leucocytosis. However, no symptom, sign, or x-ray finding is sensitive or specific for the diagnosis, because all can be caused by atelectasis, pulmonary embolism, or pulmonary edema and may be part of the clinical findings in ARDS.

Gram stain and culture of endotracheal aspirates are controversial, because specimens are likely to be contaminated with bacteria that are colonizers as well as pathogens, and a positive culture may or may not indicate infection. Bronchoscopic sampling of lower airway secretions for quantitative culture seems to yield more reliable specimens, but the effect of this approach on outcomes is controversial. Measurement of inflammatory mediators in bronchoalveolar lavage fluid may play a future role in diagnosis; eg, a concentration of soluble triggering receptor expressed on myeloid cells (a protein expressed and shed by immune cells during infection) > 5 pg/mL may help distinguish bacterial and fungal pneumonia from noninfectious causes of clinical and radiographic changes in ventilated patients. However, this approach requires further investigation, and the only finding that reliably identifies both pneumonia and the responsible organism is a blood or pleural fluid culture that is positive for a respiratory pathogen.

Prognosis

The mortality associated with hospital-acquired pneumonia due to gram-negative infection is about 25 to 50% despite the availability of effective antibiotics. Whether death is due to underlying illness or to the pneumonia itself is uncertain. Women may be at greater risk of death. The mortality rate associated with S. aureus pneumonia is 10 to 40%, in part due to the serious conditions with which it is associated (eg, need for a ventilator, advanced age, cancer chemotherapy, chronic pulmonary disease).

Treatment

A few patients may have a pneumonia risk score (see Table 5: Pneumonia: Hospital-Acquired Pneumonia Risk IndexTables) low enough to suggest that alternative diagnoses should be sought. Otherwise, treatment is with antibiotics that are chosen empirically based on local sensitivity patterns, specific patient risk factors, and the conditions noted in Table 2: Pneumonia: Community-Acquired Pneumonia in Adults Tables.

Table 5

Hospital-Acquired Pneumonia Risk Index

Factor

Points

Temperature (°C)

36.5 and 38.4

0

38.5 and ≤ 38.9

1

39 and 36

2

Blood leukocytes, μL

4,000 and 11, 000

0

< 4,000 or > 11,000

1

Band forms 50%

1

Tracheal secretions

None

0

Nonpurulent

1

Purulent

2

Oxygenation: Pao 2/Fio 2, mm Hg

> 240 or ARDS

0

240 and no ARDS

2

Pulmonary radiography

No infiltrate

0

Diffuse (or patchy) infiltrate

1

Localized infiltrate

2

Progression of infiltrate*

None

0

Progression (heart failure and ARDS excluded)

2

Growth of pathogenic bacteria on tracheal aspirate culture*

No, rare, or light growth

0

Moderate or heavy growth

1

Same bacteria as on Gram stain

1

Pao 2/Fio 2 = ratio of arterial O2 pressure to fraction of inspired O2; ARDS = acute respiratory distress syndrome.

*Criteria applicable 72 h after initial diagnosis.

Score > 6 suggests hospital-acquired pneumonia.

Score < 6 suggests alternative process.

Adapted from Singh N, Rogers P, Atwood CW, et al: Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. American Journal of Respiratory and Critical Care Medicine 162:505–511, 2000.

Indiscriminate use of antibiotics is a major contributor to development of antimicrobial resistance. Therefore, treatment may begin with initial use of broad-spectrum drugs, which are replaced by the most specific drug available for the pathogens identified by culture. Alternative strategies for limiting resistance that has not proven effective include stopping antibiotics after 72 h in patients whose pulmonary infection scores (see Table 5: Pneumonia: Hospital-Acquired Pneumonia Risk IndexTables) improve to < 6 and regularly rotating empirically chosen antibiotics (eg, q 3 to 6 mo).

Initial antibiotics: Multiple regimens exist, but all should include antibiotics that cover both resistant gram-negative and gram-positive organisms. Options include a carbapenem ( imipenem-cilastatin Some Trade Names

500 mg IV q 6 h or meropenem Some Trade Names
MERREM
Click for Drug Monograph
1 to 2 g IV q 8 h), monobactam ( aztreonam Some Trade Names
AZACTAM
Click for Drug Monograph
1 to 2 g IV q 8 h), or antipseudomonal β-lactam ( ticarcillin Some Trade Names
TICAR

3 g IV with or without clavulanic acid q 4 h, piperacillin Some Trade Names
PIPRACIL
Click for Drug Monograph
3 g IV with or without tazobactam q 4 to 6 h, ceftazidime Some Trade Names
FORTAZ
TAZICEF
Click for Drug Monograph
2 g IV q 8 h, or cefepime Some Trade Names
MAXIPIME
Click for Drug Monograph
1 to 2 g q 12 h), given alone or combined with an aminoglycoside ( gentamicin Some Trade Names
GARAMYCIN
Click for Drug Monograph
or tobramycin Some Trade Names
NEBCIN
TOBI
TOBREX
Click for Drug Monograph
1.7 mg/kg IV q 8 h or 5 to 6 mg/kg once/day or amikacin Some Trade Names
AMIKIN
Click for Drug Monograph
5 mg/kg q 8 h) and/or vancomycin Some Trade Names
VANCOCIN
Click for Drug Monograph
1 g q 12 h. Linezolid Some Trade Names
ZYVOX
Click for Drug Monograph
may be used for some pulmonary infections involving methicillin-resistant S. aureus, especially in patients who cannot take vancomycin Some Trade Names
VANCOCIN
Click for Drug Monograph
. Daptomycin Some Trade Names
CUBICIN
Click for Drug Monograph
should not be used for pulmonary infections.

Prevention

Noninvasive ventilation using continuous positive airway pressure (CPAP) or bi-level positive airway pressure (BiPAP) prevents the breach in airway defense that occurs with endotracheal intubation and eliminates the need for intubation in some patients. Semi-upright or upright positioning reduces risk of aspiration and pneumonia compared with recumbent positioning.

Continuous aspiration of subglottic secretions using a specially designed endotracheal tube attached to a suction device seems to reduce the risk of aspiration.

Selective decontamination of the oropharynx (using topical gentamicin Some Trade Names
GARAMYCIN
Click for Drug Monograph
, colistin, and vancomycin Some Trade Names
VANCOCIN
Click for Drug Monograph
cream) or of the entire GI tract (using polymyxin, an aminoglycoside or quinolone, and either nystatin Some Trade Names
MYCOSTATIN
NILSTAT
Click for Drug Monograph
or amphotericin) also seems to be effective, although it may increase the risk of colonization with resistant organisms.

Surveillance cultures and routinely changing ventilator circuits or endotracheal tubes have not been shown to decrease ventilator-associated pneumonia.

Last full review/revision November 2005

Content last modified November 2005

Back to Top

Previous: Community-Acquired Pneumonia

Next: Nursing Home–Acquired Pneumonia

Audio
Figures
Photographs
Tables
Videos
Contact UsSite MapPrivacy PolicyTerms of UseCopyright 1995-2007 Merck & Co., Inc.